⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
OIF Validates Critical Interoperability Live at OFC 2026 Through Multi-Vendor Demonstrations and Expert Panels
businesswire.com
T
CIEN
CSCO
QCOM
AVGO
MRVL
NVDA
NXPI
ADI
AMD
INTC
AMAT
KLAC
LRCX
MU
SMCI
SNPS
CDNS
KEYS
HPQ
NOK
ADTN
COHR
AMPH
ANET
ASML
AVPT
BEKE
BIIB
BMBL
BROS
BYND
CCJ
CDW
CHTR
CLVT
CRWD
CTAS
DDOG
DELL
DOCU
DOX
DT
EBAY
ENPH
ERIC
ETSY
FSLR
FTNT
GILD
GOOG
GRMN
HPE
IBM
IDXX
ILMN
INTU
ISRG
JD
JKS
KDP
LULU
MCHP
MDLZ
MELI
META
MGM
MNST
MRNA
MSFT
MTCH
MTRX
MUFG
NFLX
NTES
ORCL
PANW
PDD
PEP
PFE
PLTR
PM
PPC
PYPL
QGEN
RCL
REGN
ROKU
ROST
SBUX
SIRI
SNOW
SPOT
SWKS
SYK
TCOM
TEAM
TER
TGT
TMO
TMUS
TSLA
TTD
TXN
UAL
ULTA
UPST
VRSK
VRTX
WDC
WDAY
XEL
XOM
ZM
ZS
Growth Factors Market to Reach US$ 3.7 Bn by 2033, Expands Amid Rising Regenerative Medicine and Biopharmaceutical Innovation - Persistence Market Research
prnewswire.com
TMO
MRK
BIO
BIIB
AMGN
GILD
REGN
CRSP
NTLA
BMY
ABBV
AZN
NVS
PFE
JNJ
MRNA
BNTX
COR
STEM
ALGN
EXAS
MDLZ
BHC
CVS
UNH
CI
CNC
ELAN
ZTS
ISRG
QRVO
SWKS
AVGO
QCOM
INTC
MSFT
GOOG
AMZN
IBM
ORCL
CRM
ADBE
NFLX
DIS
MCD
SBUX
KO
PEP
PG
JPM
BAC
WFC
C
GS
MS
AXP
V
MA
HD
LOW
COST
TGT
WMT
BBY
CMCSA
VZ
T
XOM
CVX
SIRI
UBER
LYFT
NVDA
AMD
MU
AMAT
LRCX
ASML
ADI
TXN
QGEN
ILMN
VRTX
EDIT
BEAM
SRPT
ACAD
ALKS
MDT
SYK
DHR
GOOGL
U.S. Orphan Drug Market Report 2026: A $200 Billion Opportunity by 2031 - Indication, Company, Trial Phase, Marketed Status of 1400 Drugs, Drug Sales of 150 Drugs, Pricing and Dosage of 400 Drugs
globenewswire.com
BMY
GILD
JNJ
SNY
TAK
AMGN
AZN
LLY
MRK
PFE
REGN
VRTX
ABBV
ALNY
AMTX
BIIB
BMRN
CRSP
EXAS
INCY
IONS
JAZZ
NTLA
PTC
RGEN
XOM
Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity USA - English India - English
prnewswire.com
GILD
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
businesswire.com
GILD
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
businesswire.com
GILD
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
FATE
INDP
AMGN
NKTR
IBIO
TAK
SNY
INMB
CLMT
VERX
GTBP
BHVN
CHRS
GSK
BMY
MRK
ABBV
AZN
GILD
LLY
KYMR
REGN
SPRY
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
prnewswire.com
BMY
GILD
JNJ
CRSP
ALLO
CART
World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors
prnewswire.com
GILD
AZN
BMY
ABBV
BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
prnewswire.com
ABBV
AMGN
AZN
BMY
GILD
JNJ
LLY
MRK
NVS
PFE
SNY
TMO